Biomarkers for Ovarian Cancer: B2 Microglobulin
The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying ovarian cancer status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as ovarian cancer or non-ovarian cancer. The biomarkers can be detected by SELDI mass spectrometry.
1 . A method for qualifying ovarian cancer status in a subject comprising:
(a) measuring at least one biomarker in a biological sample from the subject, wherein the at least one biomarker is selected from the group consisting of the biomarkers of Table 1; and
(b) correlating the measurement with ovarian cancer status.
2 . The method of claim 1 , wherein the at least one biomarker of Table 1 is β-2 microglobulin.
3 . The method of claim 2 , wherein the at least one biomarker is measured by capturing the biomarker on an adsorbent surface of a SELDI probe and detecting the captured biomarkers by laser desorption-ionization mass spectrometry.
4 . The method of claim 2 , wherein the at least one biomarker is measured by immunoassay.
5 . The method of claim 2 , wherein the sample is serum.
6 . The method of claim 2 , wherein the correlating is performed by a software classification algorithm.
7 . The method of claim 2 , wherein ovarian cancer status is selected from ovarian cancer and non-ovarian cancer.
8 . The method of claim 2 , wherein ovarian cancer status is selected from early stage and late stage.
9 . The method of claim 2 , further comprising: (c) managing subject treatment based on the status.
10 . The method of claim 3 , wherein the adsorbent is a IMAC copper adsorbent.
11 . The method of claim 3 , wherein the adsorbent is a biospecific adsorbent.
12 . The method of claim 7 , wherein, if the measurement correlates with ovarian cancer, then managing subject treatment comprises administering an inhibitor of any of the up-regulated biomarkers of Table 1 to the subject.
13 . The method of claim 7 , further comprising: (d) measuring the at least one biomarker after subject management and correlating the measurement with disease progression.
14 . A method for determining the course of ovarian cancer comprising:
(a) measuring, at a first time, at least one biomarker in a biological sample from the subject, wherein the at least one biomarker is selected from the group consisting of the biomarkers of Table 1;
(b) measuring, at a second time, the at least one biomarker in a biological sample from the subject; and
(c) comparing the first measurement and the second measurement;
wherein the comparative measurements determine the course of the ovarian cancer.
15 . The method of claim 14 , wherein the biomarker is β-2 microglobulin.
16 . A method comprising measuring at least one biomarker in a sample from a subject, wherein the at least one biomarker is selected from the group consisting of biomarkers of Table 1.
17 . The method of claim 16 , wherein the biomarker is β-2 microglobulin.
18 . A composition comprising a purified biomolecule selected from the biomarkers of Table 1.
19 . A composition comprising a biospecific capture reagent that specifically binds a biomolecule selected from the biomarkers of Table 1.
20 . The method of claim 19 , wherein the biomarker is β-2 microglobulin.
21 . The composition of claim 20 wherein the biospecific capture reagent is an antibody.
22 . The composition of claim 20 wherein the biospecific capture reagent is bound to a solid support.
23 . A composition comprising a biospecific capture reagent bound to a biomarker of Table 1.
24 . A kit comprising:
(a) a solid support comprising at least one capture reagent attached thereto, wherein the capture reagent binds at least one biomarker from a first group consisting of the Biomarkers of Table 1; and
(b) instructions for using the solid support to detect a biomarker of Table 1.
25 . The kit of claim 24 , wherein the biomarker is β-2 microglobulin.
26 . The kit of claim 25 , wherein the solid support comprising a capture reagent is a SELDI probe.
27 . The kit of claim 25 , wherein the capture reagent is a IMAC copper adsorbent
28 . The kit of claim 25 additionally comprising: (c) a container containing at least one of the biomarkers of Table 1.
29 . The kit of claim 25 additionally comprising: (c) a biospecific chromatography sorbent.
30 . A kit comprising:
(a) a solid support comprising at least one capture reagent attached thereto, wherein the capture reagents bind at least one biomarker selected from the group consisting of the biomarkers of Table 1; and
(b) a container containing at least one of the biomarkers.
31 . The kit of claim 24 , wherein the biomarker is β-2 microglobulin.
32 . The kit of claim 31 wherein the solid support comprising a capture reagent is a SELDI probe.
33 . The kit of claims 31 additionally comprising: (c) a biospecific chromatography sorbent.
34 . The kit of claim 31 wherein the capture reagent is a IMAC copper adsorbent.
35 . A software product comprising:
a. code that accesses data attributed to a sample, the data comprising measurement of at least one biomarker in the sample, the biomarker selected from the group consisting of the biomarkers of Table 1; and
b. code that executes a classification algorithm that classifies the ovarian cancer status of the sample as a function of the measurement.
36 . A method comprising detecting a biomarker of Table 1 by mass spectrometry or immunoassay.
37 . A method comprising communicating to a subject a diagnosis relating to ovarian cancer status determined from the correlation of biomarkers in a sample from the subject, wherein said biomarkers are selected from Table 1.
38 . The method of claim 37 wherein the diagnosis is communicated to the subject via a computer-generated medium.
39 . A method for identifying a compound that interacts with biomarker of table 1, wherein said method comprises:
a) contacting a biomarker of Table 1 with a test compound; and
b) determining whether the test compound interacts with the biomarker of Table 1.
40 . A method for modulating the concentration of a biomarker of Table 1 in a cell, wherein said method comprises:
a) contacting said cell with a small molecule, wherein said small molecule inhibits expression of a biomarker of Table 1.
41 . A method of treating a condition in a subject, wherein said method comprises:
administering to a subject a therapeutically effective amount of a small molecule, wherein said small molecule inhibits expression of a biomarker of Table 1.
42 . The method of claim 41 wherein said condition is ovarian cancer.